BTK and B-cell chronic lymphocytic leukemia: The most frequent BTK mutation emerging in CLL patients on ibrutinib and acalabrutinib is in their binding site (C481 residue), causing an aminoacidic substitution (most commonly C481S) and resulting in a binding at a lower affinity [62,63,64].